Comparative neuropathological evaluation of pT217 immunoreactivity in human and transgenic mouse tauopathies

Clicks: 11
ID: 333257
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #50 of 54 articles by views in Journal of Neuropathology & Experimental Neurology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Tau phosphorylation at threonine 217 (pT217) has been increasingly recognized as a biomarker for Alzheimer disease (AD), but its neuropathological distribution and the performance of available antibodies remain to be fully characterized. In this study, we performed a comparative evaluation of a recombinant rabbit monoclonal anti-pT217 antibody (mAb) using immunohistochemical and biochemical analyzes in human and transgenic mouse tauopathies and compared results to those of a commercially available anti-pT217 antibody and the AT8 antibody. In rTg4510 mice, the anti-pT217 mAb detected pathological tau aggregates with high sensitivity, including hyperphosphorylated tau species identified by biochemical fraction. In human postmortem brain tissues (AD, Pick disease, progressive supranuclear palsy, corticobasal degeneration), quantitative image analysis demonstrated labeling of a broad range of tau lesions, including neurofibrillary tangles, neuropil threads, tufted astrocytes, astrocytic plaques, and Pick bodies. The overall detectability was comparable to that of AT8 and similar to or modestly > that of a representative commercial anti-pT217 antibody. These findings indicate that pT217 is widely present across tauopathies and suggest that the recombinant anti-pT217 mAb provides a sensitive and reproducible tool for neuropathological assessment. Together, these results provide a framework for evaluating anti-pT217 antibodies in neuropathological studies.
Reference Key
openalex_W7223117288 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Emi Higashiizumi, Hiroshi Shimizu, Takaaki Nishikawa, Koichi Koyama, Haruki Nakagawa, Naoko Nakatani, Taro Tachibana, Melissa Erin Murray, Dennis W. Dickson, Akiyoshi Kakita, Hitoshi Shimada, Naruhiko Sahara
Are you one of these authors? Claim your profile
Journal Journal of Neuropathology & Experimental Neurology
Year 2026
DOI
10.1093/jnen/nlag103
URL
https://doi.org/10.1093/jnen/nlag103
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.